Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial

Human Reproduction

Volumn 15, Issue 7, 2000, Pages 1490-1498

  Abyholm T ^b   Barlow, D ^c   Devroey, P ^d   Diedrich, K ^e   Donnez, J ^f   Von During V ^g   Fauser, B ^h   Hamberger, L ⁱ   Hillensjo T ^j   Hugues, J N ^k   Jansen, C ^l   Kahn, J ^m   Blaabjerg, J ⁿ   Olivennes, F ^o   Pellicer, A ^p   Pavlou, S ^q   Rabe, T ^r   Rutherford, A ^s   Tarlatzis, B ^t   Westergaard, L ^u   Borm, G ^a   Mannaerts, B ^a   more..

^a NV ORGANON   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e UNIVERSITY OF LÜBECK   (Germany)

^f FREE UNIVERSITY OF BRUSSELS   (Belgium)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j Fertilitetscentrum   (Sweden)

^k HÔPITAL JEAN VERDIER   (France)

^l Diaconessenhuis   (Netherlands)

^m Fertility Clinic Ciconia   (Denmark)

ⁿ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^o HÔPITAL ANTOINE BÉCLÈRE   (France)

^p INSTITUTO VALENCIANO DE INFERTILIDAD   (Spain)

^q Mitera Fertility and IVF Unit   (Greece)

^r UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^s LEEDS GENERAL INFIRMARY   (United Kingdom)

^t Infertility IVF Centre 'Geneki Cliniki'   (Greece)

^u ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

Buserelin; Ganirelix; GnRH agonist; GnRH antagonist; ICSI; IVF; Ovarian stimulation; Recombinant FSH

Indexed keywords

BUSERELIN; BUSERELIN ACETATE; CHORIONIC GONADOTROPIN; ESTRADIOL; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OOCYTE; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PHASE 3 CLINICAL TRIAL; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033807688     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.7.1490     Document Type: Article

References (35)

1. Comparison of different doses of gonadotrophin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation
2. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles
3. Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles
4. The combination of estimates from different experiments
5. Gonadotropin-releasing hormone agonist use in assisted reproduction cycles: The influence of long and short regimens on pregnancy rates
6. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization
7. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation
8. Cetrorelix in controlled ovarian stimulation for ART: Results of phase III, multiple dose treatment
9. Preserved pituitary response under ovarian stimulation with HMG and GnRH-antagonists (Cetrorelix) in women with tubal infertility
10. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle
11. Comparison between flare-up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program
12. Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (ganirelix) administered by intranasal spray
13. A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH-antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone
14. A novel regimen of gonadotrophin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: Controlled restoration of gonadotrophin secretion and ovulation induction
15. Gene expression of gonadotrophin-releasing hormone, but not its receptor, in human endometrium and decidua
16. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist
17. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and GnRH antagonist ganirelix (Org 37462)
18. High doses of GnRH antagonist in IVF do not adversely effect the outcome of subsequent freezethaw cycles
19. GnRH receptors in human granulosa cells: Anatomical localization and characterization autoradiographic study
20. Improved pregnancy outcome with gonadotrophin-releasing hormone agonist (GnRHa) stimulation is due to improvement in oocytes quantity rather than quality
21. The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer
22. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome
23. Gonadotrophin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyper-stimulation: Cycle performance and in vitro steroidogenesis of granulosa-lutein cells
24. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotrophin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)
25. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Orgalutran): Part I. Absolute bioavailability of 0.25 mg ganirelix after single subcutaneous injection in healthy female volunteers
26. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Orgalutran): Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers
27. Triggering of ovulation by a gonadotrophin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist
28. Ovarian effects of GnRH antagonists
29. A prospective, randomised, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization
30. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotrophin-releasing hormone antagonist (ganirelix) with minimal histamine-releasing properties: Studies in postmenopausal women
31. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle
32. The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization
33. Minimisation: The platinum standard for trials?
34. Effects of GnRH-agonist and antagonists on steroid production in rat and human granulosa cells
35. A general parametric approach to the meta-analysis of randomized clinical trials